These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

226 related items for PubMed ID: 17083506

  • 1. The need for previously untreated patient population studies in understanding the development of factor VIII inhibitors.
    Gomperts ED.
    Haemophilia; 2006 Nov; 12(6):573-8. PubMed ID: 17083506
    [Abstract] [Full Text] [Related]

  • 2. The multifactorial etiology of inhibitor development in hemophilia: genetics and environment.
    Gouw SC, van den Berg HM.
    Semin Thromb Hemost; 2009 Nov; 35(8):723-34. PubMed ID: 20169509
    [Abstract] [Full Text] [Related]

  • 3. Characteristics of inhibitors in mild/moderate haemophilia A.
    Peerlinck K, Jacquemin M.
    Haemophilia; 2006 Dec; 12 Suppl 6():43-7. PubMed ID: 17123393
    [Abstract] [Full Text] [Related]

  • 4. Genetic risk factors for inhibitors to factors VIII and IX.
    Oldenburg J, Pavlova A.
    Haemophilia; 2006 Dec; 12 Suppl 6():15-22. PubMed ID: 17123389
    [Abstract] [Full Text] [Related]

  • 5. Assessing risk factors: prevention of inhibitors in haemophilia.
    Chambost H.
    Haemophilia; 2010 Mar; 16 Suppl 2():10-5. PubMed ID: 20132333
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Epidemiology of inhibitor formation with recombinant factor VIII replacement therapy.
    Peerlinck K, Hermans C.
    Haemophilia; 2006 Nov; 12(6):579-90. PubMed ID: 17083507
    [Abstract] [Full Text] [Related]

  • 9. The epidemiology of factor VIII inhibitors.
    Hay CR.
    Haemophilia; 2006 Dec; 12 Suppl 6():23-8; discussion 28-9. PubMed ID: 17123390
    [Abstract] [Full Text] [Related]

  • 10. Epidemiology of inhibitors in haemophilia A.
    Kreuz W, Escuriola-Ettingshausen C, Martinez-Saguer I, Güngör T, Kornhuber B.
    Vox Sang; 1996 Dec; 70 Suppl 1():2-8. PubMed ID: 8869461
    [Abstract] [Full Text] [Related]

  • 11. Immunological aspects of inhibitor development.
    Reding MT.
    Haemophilia; 2006 Dec; 12 Suppl 6():30-5; discussion 35-6. PubMed ID: 17123391
    [Abstract] [Full Text] [Related]

  • 12. Inhibitor development.
    Astermark J, Lacroix-Desmazes S, Reding MT.
    Haemophilia; 2008 Jul; 14 Suppl 3():36-42. PubMed ID: 18510520
    [Abstract] [Full Text] [Related]

  • 13. Overview of inhibitors.
    Astermark J.
    Semin Hematol; 2006 Apr; 43(2 Suppl 4):S3-7. PubMed ID: 16690373
    [Abstract] [Full Text] [Related]

  • 14. Inhibitor development: patient-determined risk factors.
    Astermark J.
    Haemophilia; 2010 May; 16(102):66-70. PubMed ID: 19298384
    [Abstract] [Full Text] [Related]

  • 15. Why do inhibitors develop? Principles of and factors influencing the risk for inhibitor development in haemophilia.
    Astermark J.
    Haemophilia; 2006 Jul; 12 Suppl 3():52-60. PubMed ID: 16683997
    [Abstract] [Full Text] [Related]

  • 16. Relationship between factor VIII mutation type and inhibitor development in a cohort of previously untreated patients treated with recombinant factor VIII (Recombinate). Recombinate PUP Study Group.
    Goodeve AC, Williams I, Bray GL, Peake IR.
    Thromb Haemost; 2000 Jun; 83(6):844-8. PubMed ID: 10896236
    [Abstract] [Full Text] [Related]

  • 17. Factor VIII inhibitors in patients with hemophilia A: epidemiology of inhibitor development and induction of immune tolerance for factor VIII.
    Kreuz W, Becker S, Lenz E, Martinez-Saguer I, Escuriola-Ettingshausen C, Funk M, Ehrenforth S, Auerswald G, Kornhuber B.
    Semin Thromb Hemost; 1995 Jun; 21(4):382-9. PubMed ID: 8747701
    [Abstract] [Full Text] [Related]

  • 18. Inhibitors of factor VIII in hemophilia.
    Lacroix-Desmazes S, Dimitrov JD, Repesse Y.
    N Engl J Med; 2009 Jul 16; 361(3):308; author reply 310. PubMed ID: 19605840
    [No Abstract] [Full Text] [Related]

  • 19. Immune regulatory gene polymorphisms as predisposing risk factors for the development of factor VIII inhibitors in Indian severe haemophilia A patients.
    Pinto P, Ghosh K, Shetty S.
    Haemophilia; 2012 Sep 16; 18(5):794-7. PubMed ID: 22630053
    [Abstract] [Full Text] [Related]

  • 20. Novel therapies for immune tolerance in haemophilia A.
    Collins PW.
    Haemophilia; 2006 Dec 16; 12 Suppl 6():94-100; discussion 100-1. PubMed ID: 17123401
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.